Real World Outcomes with Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody: A Single Center Experience for Relapsed/ Refractory Multiple Myeloma (RRMM)

被引：0
|
作者：
Gill, Sarvarinder Kaur [1 ]
Fleming, Erika [2 ]
Gebre, Helen [1 ]
Bangolo, Ayrton, I [3 ]
Siegel, David S. [4 ,5 ]
Vesole, David H. [6 ]
Biran, Noa [6 ]
Parmar, Harsh [6 ]
Phull, Pooja [6 ]
机构：
[1] Hackensack Univ Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA
[2] Hackensack Meridian Sch Med, Nutley, NJ USA
[3] Hackensack Univ Med Ctr, John Theurer Canc Ctr, Edgewater, NJ USA
[4] Hackensack Meridian Hlth, John Theurer Canc Ctr, Div Multiple Myeloma, Hackensack, NJ USA
[5] Ctr Discovery & Innovat, Hackensack, NJ USA
[6] Hackensack Univ Med Ctr, Div Multiple Myeloma, John Theurer Canc Ctr, Hackensack, NJ USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-210350
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：7047 / 7048
页数：2
相关论文
共 50 条
  • [1] Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody
    Chari, Ajai
    Minnema, Monique C.
    Berdeja, Jesus G.
    Oriol, Albert
    van de Donk, Niels W. C. J.
    Rodriguez-Otero, Paula
    Askari, Elham
    Mateos, Maria-Victoria
    Costa, Luciano J.
    Caers, Jo
    Verona, Raluca
    Girgis, Suzette
    Yang, Shiyi
    Goldsmith, Rachel B.
    Yao, Xiang
    Pillarisetti, Kodandaram
    Hilder, Brandi W.
    Russell, Jeffery
    Goldberg, Jenna D.
    Krishnan, Amrita
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (24): : 2232 - 2244
  • [2] Targeting GPRC5D With Talquetamab: A New Frontier in Bispecific Antibody Therapy for Relapsed/Refractory Multiple Myeloma
    Shaver, Jacob
    Horton, Daniel
    Halford, Zachery
    ANNALS OF PHARMACOTHERAPY, 2025, 59 (04) : 350 - 363
  • [3] Characterization of dysgeusia and xerostomia in patients with multiple myeloma treated with the T-cell redirecting GPRC5D bispecific antibody talquetamab
    A. M. G. A. Laheij
    N. W. C. J. van de Donk
    Supportive Care in Cancer, 2024, 32
  • [4] Characterization of dysgeusia and xerostomia in patients with multiple myeloma treated with the T-cell redirecting GPRC5D bispecific antibody talquetamab
    Laheij, A. M. G. A.
    van de Donk, N. W. C. J.
    SUPPORTIVE CARE IN CANCER, 2024, 32 (01)
  • [5] Structural Basis for the Recognition of GPRC5D by Talquetamab, a Bispecific Antibody for Multiple Myeloma
    Jeong, Jihong
    Park, Junhyeon
    Mo, Geun Young
    Shin, Jinwoo
    Cho, Yunje
    JOURNAL OF MOLECULAR BIOLOGY, 2024, 436 (20)
  • [6] Changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody therapy in patients with relapsed refractory multiple myeloma (RRMM).
    Janardan, Abhishek
    Lindsay, Hammons
    Szabo, Aniko
    Bhatlapenumarthi, Vineel
    Annyapu, Evanka
    Dhakal, Binod
    Narra, Ravi Kishore
    Al Hadidi, Samer
    Radhakrishnan, Sabarinath Venniyil
    Bhutani, Divaya
    Thanendrarajan, Sharmilan
    Siegfried, Janz
    Zangari, Maurizio
    Lentzsch, Suzanne
    van Rhee, Frits
    D'Souza, Anita
    Chakraborty, Rajshekhar
    Schinke, Carolina D.
    Mohan, Meera
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] Anti-GPRC5D/CD3 Bispecific T-Cell-Redirecting Antibody for the Treatment of Multiple Myeloma
    Kodama, Tatsushi
    Kochi, Yu
    Nakai, Waka
    Mizuno, Hideaki
    Baba, Takeshi
    Habu, Kiyoshi
    Sawada, Noriaki
    Tsunoda, Hiroyuki
    Shima, Takahiro
    Miyawaki, Kohta
    Kikushige, Yoshikane
    Mori, Yasuo
    Miyamoto, Toshihiro
    Maeda, Takahiro
    Akashi, Koichi
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (09) : 1555 - 1564
  • [8] Functional Characterization of GPRC5D alteration and Its Impact on Talquetamab Resistance in Relapsed/ Refractory Multiple Myeloma
    Han, Seungbin
    Munawar, Umair
    Haertle, Larissa
    Vogt, Cornelia
    Nerreter, Silvia
    Teufel, Eva
    Zhou, Xiang
    Steinhardt, Max
    Eisele, Florian
    Raab, Peter
    Truger, Marietta
    Dorado, Sara
    Barrio, Santiago
    Haferlach, Claudia
    Martinez-Lopez, Joaquin
    Einsele, Hermann
    Rasche, Leo
    Waldschmidt, Johannes M.
    Koertum, K. Martin
    BLOOD, 2023, 142
  • [9] Real-World Clinical Outcomes of Teclistamab and Talquetamab in Relapsed/Refractory Multiple Myeloma (RRMM): A UK Single-Centre Experience
    Feixas, Pablo Tenorio
    Cox, Catrin
    Peer, Xavier
    Cuthill, Kirsty
    Benjamin, Reuben
    Gunawan, Arief
    Cuadrado, Maria
    de Farias, Madson Correia
    Jones, John
    Shin, Jin-Sup
    Batool, Asma
    Bowcock, Stella
    Omer, Musab
    Tawde, Prachi
    Bailey, Katharine
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S92 - S92
  • [10] Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma
    Granger, Katelynn
    Gaffney, Kelly J.
    Davis, James A.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (03) : 722 - 726
12345